Stockpolly
Search
Delisting risk
KTTA · NASDAQ · Biotechnology

Pasithea Therapeutics (KTTA)

Clinical-stage developer of an oral MEK inhibitor for NF1-related tumors and advanced cancers.

$0.5876
At close+0.02 (+4.37%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
4544334431056
Research & development23222222132,9423,686
22221222281,9342,028
General & administrative20221022281,9342,028
Other expenses0000000000−4,872−5,708
Operating income−4−5−4−4−3−3−4−4−3−10−5−6
000000000020
Interest income000000000000
Other non-operating income000000000000
Income before tax−4−5−4−4−3−3−4−4−3−10−3−5
Net income from continuing operations−4−5−4−4−3−3−4−4−3−10−3−5
Discontinued operations000000000000
Net income−4−5−4−4−3−3−4−4−3−10−3−5
EPS, basic−$2.87−$4.85−$3.70−$3.71−$2.87−$2.90−$3.25−$0.66−$0.41−$0.89−$0.41−$0.75
EPS, diluted−$2.87−$4.85−$3.70−$3.71−$2.87−$2.90−$3.25−$0.66−$0.41−$0.89−$0.41−$0.75
Weighted average shares, basic111111167777
Weighted average shares, diluted111111167777
EBITDA−4−5−4−4−3−3−4−4−3−10−5−6
Depreciation & amortization000000000000
EBIT−4−5−4−4−3−3−4−4−3−10−5−6